|
|
| | LIT-927 Basic information |
| Product Name: | LIT-927 | | Synonyms: | CS-2869;LIT-927;2(1H)-Pyrimidinone, 4-(4-chlorophenyl)-6-(4-hydroxy-3-methoxyphenyl)-;4-(4-Chlorophenyl)-6-(4-hydroxy-3-methoxyphenyl)pyrimidin-2(1H)-one | | CAS: | 2172879-52-4 | | MF: | C17H13ClN2O3 | | MW: | 328.75 | | EINECS: | | | Product Categories: | API | | Mol File: | 2172879-52-4.mol |  |
| | LIT-927 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:66.0(Max Conc. mg/mL);200.76(Max Conc. mM) | | form | A solid | | color | Light yellow to yellow |
| | LIT-927 Usage And Synthesis |
| Biochem/physiol Actions | LIT-927 is an orally active CXCL12 (SDF1) neutraligand (Kd = 267) that selectively neutralizes CXCL12, but not CCL17, CCL22, CCL5, or CCL2 activity in cultures (10 μM LIT-927 against 5 nM chemokine-induced calcium mobilization). LIT-927 reduces eosinophil recruitment in a murine allergic airway hypereosinophilia model in vivo (330 nmol/kg intranasal, 350 nmol/kg ip. or 1400 μmol/kg po.), offering greatly improved oral activity and solubility than Chalcone-4, and exhibiting little side-effects when compared with dexamethasone or CXCR4 antagonist AMD3100. |
| | LIT-927 Preparation Products And Raw materials |
|